JBIO Q4 2024 Earnings — Jade Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

JBIOJade Biosciences, Inc.

$491M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$8,000

Operating Income

-$6M

Net Income

-$5M

EPS (Diluted)

$-6.56

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$80M

Total Liabilities

$4M

Stockholders' Equity

$76M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$8,000	-$28,000	+71.4%
Operating Income	-$6M	-$22M	+71.0%
Net Income	-$5M	-$20M	+73.4%